Total Funding
93
64
Total FundingPost-IPO Equity raised
Growth Score
5 pts
Heat Score
6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
2073
Erasca is a developer of oncology drugs intended to provide precision oncology options.
- Jonathan Lim: Chairman, CEO, and Co-FounderPast Role: Ignyta, Chairman, CEO, President and Co-Founder
- David Chacko: Chief Financial Officer
About the Company
Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations,
providing patients with new potential solutions to not just treat but cure cancer.
Erasca was founded in 2018 and is headquartered in San Diego, California.
